Dynavax and UCB Pharma in strategic partnering agreement
US-based Dynavax Technologies Corporation has entered into an agreement with UCB Pharma, the pharmaceuticals division of UCB Group, in which Dynavax licensed the technology, know-how and preclinical and clinical data related to its ragweed and grass allergy immunotherapy programs to UCB on an exclusive, worldwide basis. Dynavax also granted UCB an option to license Dynavax's peanut allergy programme.
US-based Dynavax Technologies Corporation has entered into an agreement with UCB Pharma, the pharmaceuticals division of UCB Group, in which Dynavax licensed the technology, know-how and preclinical and clinical data related to its ragweed and grass allergy immunotherapy programs to UCB on an exclusive, worldwide basis. Dynavax also granted UCB an option to license Dynavax's peanut allergy programme.
Under the agreement, Dynavax received an up-front payment and may earn milestone payments based on achieving defined clinical and regulatory objectives. In addition, UCB has agreed to fund continued r&d of the licensed programmes, as well as costs related to regulatory filings and potential product launch, sales and marketing. If any of the licensed product candidates are successfully developed and approved for sale, Dynavax will receive royalties on sales. Dynavax has retained an option to co-promote any approved product in the US under specified circumstances.